Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature.
Ruojun WangShaomin ZhongPing TuRuoyu LiMingyue WangPublished in: Dermatologic therapy (2019)
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are spectrum of rare, acute, and life-threatening delayed-type drug hypersensitivity reactions that are associated with high mortality rates. However, no therapeutic standard has been proposed for SJS/TEN. Here, we report a case of a patient diagnosed with Stevens-Johnson syndrome whose disease progression was halted by a single dose of etanercept and was treated successfully. In addition, we reviewed the literature reporting patients with SJS/TEN treated with similar regimens.
Keyphrases
- combination therapy
- case report
- rheumatoid arthritis
- drug induced
- systematic review
- ankylosing spondylitis
- rheumatoid arthritis patients
- juvenile idiopathic arthritis
- disease activity
- high dose
- adverse drug
- type diabetes
- cardiovascular events
- low dose
- systemic lupus erythematosus
- intensive care unit
- quantum dots
- wound healing
- aortic dissection